Log in

Agile Therapeutics Stock Forecast, Price & News

+0.08 (+2.86 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $2.88
50-Day Range
MA: $3.08
52-Week Range
Now: $2.88
Volume977,874 shs
Average Volume2.54 million shs
Market Capitalization$251.42 million
P/E RatioN/A
Dividend YieldN/A
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Read More
Agile Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AGRX



Sales & Book Value

Annual SalesN/A
Book Value$0.77 per share


Net Income$-18,610,000.00


Market Cap$251.42 million
Next Earnings Date10/26/2020 (Estimated)
+0.08 (+2.86 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

How has Agile Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Agile Therapeutics' stock was trading at $1.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGRX stock has increased by 48.5% and is now trading at $2.88.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Agile Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agile Therapeutics

When is Agile Therapeutics' next earnings date?

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Agile Therapeutics

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics Inc (NASDAQ:AGRX) announced its quarterly earnings results on Tuesday, August, 11th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02.
View Agile Therapeutics' earnings history

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics issued an update on its fourth quarter 2020 After-Hours earnings guidance on Monday, September, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1-2 million.

What price target have analysts set for AGRX?

5 analysts have issued 1-year price targets for Agile Therapeutics' shares. Their forecasts range from $6.00 to $9.00. On average, they expect Agile Therapeutics' stock price to reach $7.75 in the next year. This suggests a possible upside of 169.1% from the stock's current price.
View analysts' price targets for Agile Therapeutics

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 4,960,000 shares, an increase of 13.5% from the July 30th total of 4,370,000 shares. Based on an average trading volume of 1,700,000 shares, the short-interest ratio is presently 2.9 days.
View Agile Therapeutics' Short Interest

Who are some of Agile Therapeutics' key competitors?

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include Opko Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Novavax (NVAX) and Pfizer (PFE).

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the following people:
  • Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
  • Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
  • Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
  • Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nuveen Asset Management LLC (0.37%), SG Americas Securities LLC (0.28%), Bank of New York Mellon Corp (0.24%), Charles Schwab Investment Management Inc. (0.20%), Two Sigma Advisers LP (0.20%) and California Public Employees Retirement System (0.16%). Company insiders that own Agile Therapeutics stock include Abhijeet J Lele, Alfred Altomari, Dennis Reilly, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for Agile Therapeutics

Which major investors are selling Agile Therapeutics stock?

AGRX stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, and Advisor Group Holdings Inc..
View insider buying and selling activity for Agile Therapeutics

Which major investors are buying Agile Therapeutics stock?

AGRX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, SG Americas Securities LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, Two Sigma Advisers LP, Jane Street Group LLC, and New York State Common Retirement Fund. Company insiders that have bought Agile Therapeutics stock in the last two years include Abhijeet J Lele, Alfred Altomari, Dennis Reilly, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Agile Therapeutics

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $2.88.

How big of a company is Agile Therapeutics?

Agile Therapeutics has a market capitalization of $251.42 million. The specialty pharmaceutical company earns $-18,610,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe.

What is Agile Therapeutics' official website?

The official website for Agile Therapeutics is www.agiletherapeutics.com.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.